In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 5 of 5

TitleConsultationTypeConsultation end date
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]Draft guidanceTechnology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma [ID6211]Draft guidanceTechnology appraisal guidance
Delgocitinib for treating moderate to severe chronic hand eczema [ID6408]Draft guidanceTechnology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Draft guidanceTechnology appraisal guidance
Teprotumumab for treating thyroid eye disease [ID6432]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All